The most recent assessment of available evidence on lung cancer
screening with a sensitive modality (computed tomography) found that
we cannot conclude that such screening provides a mortality benefit.
The main reason for this, is that there is no available trial that
compares CT screening to no screening over an adequate duration of
time. Of note, false positive results were very common and tumors
found on screening had different characteristics from those found